Skip to main content

Improper preanalytical processes on peripheral blood compromise RNA quality and skew the transcriptional readouts of mRNA and LncRNA.

He Y, Dong L, Yi H, Zhang L, Shi X, Su L, Gan B, Guo R, Wang Y, Luo Q, Li X

Publication: Front Genet (2022) • Vol 13 • Page 1091685PMID: 36685907View on PubMed

Purpose

The purpose of this paper was to compare RNA yield, purity, integrity, and levels of select mRNAs among RNA isolated from white blood cells using three different commercial kits and Trizol reagent. Potential effects of processing delays on RNA endpoints were also investigated using one kit after different processing delays.  Additionally, the authors investigated if the extraction kit altered the differential expression of genes in plasma collected from patients with chronic obstructive pulmonary disease (COPD) and triple negative breast cancer (TNBC) compared to healthy controls.

Conclusion

All three commercial RNA extraction kits extracted less RNA than the method using Trizol reagent, but RNA purity and integrity were comparable when extraction was with Trizol or Kit 1. The RNA integrity numbers (RINs) were much lower when RNA was extracted with Kit 3 compared to all other methods but this difference was partially attenuated by the addition of β-mercaptoethanol to the lysis buffer. The number of copies of β-Actin was dependent on extraction kit, with the highest number of copies found when extraction was with Kit 1. The magnitude and direction of differential expression of genes in plasma collected from COPD and TNBC patients relative to controls was dependent on the RNA extraction kit used. The authors attributed these differences to RNA integrity.

RNA yields, purity (ratio of absorbance at 260 to 280 nm), and integrity decreased with pre-extraction storage of blood at room temperature, but differences were not significant when stored for ≤24 h. In contrast to the other markers evaluated, a significant decrease in the number of copies of β-actin was found when blood was stored for 24 h; thus, the authors conclude blood should be stored for ≤12 h before RNA extraction.

Studies (2)

Purpose

The purpose of this study was to compare RNA yield, purity, integrity, and levels of specific mRNAs among RNA isolated from white blood cells using three different commercial kits. Additionally, the authors investigated if the extraction kit used altered differential expression of genes in plasma that was collected from patients with chronic obstructive pulmonary disease (COPD) and triple negative breast cancer (TNBC) compared to healthy controls. Blood of 30 volunteers (diagnosis not specified) was centrifuged at 1,500 g for 10 min at 4°C. Red cell lysis buffer was added to the buffy coat and then the specimen was centrifuged (conditions not specified).  RNA was extracted from the white cells using Trizol reagent, and three different unspecified commercial kits. Kit 1 added β-mercaptoethanol (β-ME) to reduce disulfide bonds during lysis and Kit 2 used guanidinium thiocyanate–phenol for lysis, but the authors state Kit 3 did not include an RNase inactivator.  RNA yields and purity were assessed by spectrophotometer. RNA integrity was evaluated by Bioanalyzer. Levels of CXCL12, SLA2, ENST00000 502,883.1, HIT000 648,516, XR_429541.1 HMOX1, TLR4, TGFβ1, TRAF6, MALAT-1, ATB, H19, and β-Actin were quantified by real-time RT-PCR. To determine if kit choice would affect the diagnosis-specific differences in transcript levels,  RNA was extracted from blood of three healthy controls, three patients with COPD, and one patient with triple negative breast cancer (TNBC) using three extraction kits and the fold difference in expression in patients relative to healthy controls was calculated.

Summary of Findings

All three commercial RNA extraction kits yielded less RNA than the method using Trizol reagent (P<0.05), and extraction with Kit 3 yielded significantly less RNA than Kit 1 and 2 (P<0.05). OD 260/280 ratios were significantly higher when RNA was obtained using Kit 3 than the Trizol method (P<0.001), Kit 1 (P<0.05), or Kit 2(P<0.05), indicating the presence of protein contaminants. Further, RNA integrity numbers (RINs) were highest when extraction was with Kit 1 (9.7 ± 0.3) followed by Trizol (8.9 ± 02) and Kit 2 (8.6 ± 0.4);further, much lower RINs were observed when extraction was with Kit 3 (2.5 ± 0.2).  RINs were significantly lower when Kit 2 was used rather than Kit 1 or Trizol (P<0.001, both) and were much lower when extraction was with Kit 3 rather than any of the other methods (P<0.001, all). When β-mercaptoethanol was added to the lysis buffer in Kit 3, the RIN increased from 2.5 ± 0.2 to 7.0 ± 1.4. Extraction with Kit 1 yielded more copies of β-Actin than when extraction was with Kit 2 (P<0.05) or Kit 3 (P<0.001), and extraction with Kit 2 yielded more copies than Kit 3 than the other methods examined (P<0.001).

Importantly, when RNA was extracted with Kit 1 and Kit 2 the relative expression of CXCL12 was 3-fold and 2.2-fold higher, respectively, in patients with COPD than healthy controls, but was 36.20-fold higher when Kit 3 was used. Similarly, COPD patients had much higher expression of SLA2 (124.60-fold), ENST00000 502,883.1 (117.15-fold), HIT000 648,516 (32.11-fold) and XR_429541.1 (135.17-fold) than healthy controls when RNA was extracted with Kit 3, but these differences were <10 fold when extraction was with Kit 1 or Kit 2. In contrast, relative levels of HMOX1 were much lower in COPD patients relative to healthy controls when RNA was extracted with Kit 3 (0.03-fold), COPD patients had higher levels of HMOX2 than healthy controls when RNA was extracted with Kit 1 or Kit 2 (1.69-fold and 1.11-fold, respectively). As observed with COPD specimens, relative gene expression in blood from TNBC patients compared to those from healthy donors was dependent on the extraction kit used. For example, TRAF6 was 1.8-fold higher in blood from TNBC patients when extraction was with Kit 1, comparable to healthy controls when extraction was with Kit 2, and 449-fold higher in TNBC patients when extraction was with Kit 3.

  • Biospecimens

    CellWhite Cells
  • Preservation Types

    None (Fresh)
  • Diagnoses

    Not specified
    Normal
    Chronic Obstructive Pulmonary Disease (COPD)
    NeoplasticCarcinoma
  • Platforms

    RNAAutomated electrophoresis/Bioanalyzer
    RNASpectrophotometry
    RNAReal-time qRT-PCR
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionDiagnosis/ patient condition
    COPD
    Healthy
    TNBC
    Analyte Extraction and PurificationAnalyte isolation method
    Trizol
    Unspecified Kit with guanidinium thiocyanate–phenol for lysis (Kit 2)
    Unspecified Kit with no RNAse inactivator (Kit 3)
    Unspecified Kit with β-mercaptoethanol (Kit 1)
    Analyte Extraction and PurificationRNase inactivation
    None
    β-mercaptoethanol